Regardless of this general increase in GFAP levels observed in these disorders and injuries, GFAP may be applied in context with other biomarkers for differential diagnosis, e.g., GFAP, together with the glial-specific S100 calcium binding protein B (S100β) may hold the potential to distinguish between CJD and AD (191). The gene discussed is S100B; the disease is Creutzfeldt Jacob disease.